

## Pharma & Healthcare Update

November 16, 2011

### FDI IN PHARMA STAYS AT 100% BUT WITH CERTAIN RESTRICTIONS

The pharma and healthcare sector in India has been benefiting from 100% Foreign Direct Investment (FDI) under the automatic route i.e., without the need for approval of the Foreign Investment Promotion Board (FIPB). In recent times, however, certain ministries and Non-Governmental Organizations have recommended restricting FDI to 49% in Indian companies. This recommendation arose as a result of some acquisitions of Indian pharma companies (including generic companies) by foreign pharma companies. It was felt that such acquisitions would lead to a significant rise in the cost of the drugs in India. Further, it was felt that if most of the generic companies are acquired by foreign companies, the option of compulsory licensing available under the Indian Patents Act, 1970 may not be availed by such companies.

Having given due consideration to the concerns raised by all, the Prime Minister of India convened a meeting of a high level committee involving certain ministries and government agencies on October 11, 2011.

This high level committee headed by the Prime Minister concluded that FDI in the pharmaceuticals sector would continue to stay at its previous level of 100%, but with certain restrictions. It was decided that the FDI in all Brownfield projects in the pharma sector will henceforth be scrutinized by the FIPB as an interim measure until the Government comes up with a comprehensive policy to regulate such investments. However, the Government has exempted FDI in Greenfield projects from any prior FIPB approval requirement.

It is also proposed that in future, all Brownfield investments will be scrutinized and approved by the Competition Commission of India (CCI).

It seems that the current (FIPB) and the proposed (CCI) approval requirements may act as a speed breaker for potential foreign investors as they may have to show that their intention is not to collude or undertake predatory pricing or any such anti-competitive practice. Bringing in the CCI and FIPB approvals collectively for brownfield projects may burden the foreign pharma companies with certain pre-conditions to be observed in undertaking their business ventures, which the FIPB/CCI may impose upon them, such as divestiture of product line or division of business, if the approving authority finds that the proposed arrangement may lead to concentration. However, the industry has welcomed the move by the Government to continue to allow 100% FDI in the pharma sector and not restricting it to 49%.

### UPCOMING GUIDELINES/REGULATIONS IN THE CLINICAL TRIALS SECTOR:

India has been a preferred destination for conducting clinical trials in order to test the safety and efficacy of various drugs before they are approved for launching in the market. The authorities in India have been expressing concerns over the adverse reactions, injury or death of patients participating in such clinical trials and compensation provided to them or their relatives by a sponsor pharma company that has conducted the trials. To constantly regulate and streamline the clinical trials sector, conscious efforts are made to either amend the existing regulations or introduce specific new regulations/guidelines.

To this effect, the Drugs Controller General of India (DCGI) has recently issued draft guidelines on reporting serious adverse events occurring in clinical trials in order to streamline the process of reporting such events to the drugs authorities in India. These guidelines propose to serve as a guidance document for the pharmaceutical industry to achieve consistency and completeness in the data submitted to the drugs authorities.

Moreover, when it comes to compensating the victims of clinical trials (in instances of injury or death of the study subjects), the law in India is pretty much silent on the specific obligations of stake holders especially the sponsor companies in clinical trials. The law does not specifically obligate the sponsor to voluntarily provide compensation, in the absence of a claim against the sponsor. The Indian Council

## Proud Moments

**Benchmark Litigation Asia-Pacific:** Tier 1 for Government & Regulatory and Tax  
*2020, 2019, 2018*

**Legal500 Asia-Pacific:** Tier 1 for Tax, Investment Funds, Labour & Employment and TMT  
*2020, 2019, 2018, 2017, 2016, 2015, 2014, 2013, 2012*

**Chambers and Partners Asia Pacific:** Band 1 for Employment, Lifesciences, Tax and TMT  
*2020, 2019, 2018, 2017, 2016, 2015*

**IFLR1000:** Tier 1 for Private Equity and Project Development: Telecommunications Networks.  
*2020, 2019, 2018, 2017, 2014*

**AsiaLaw Asia-Pacific Guide 2020:** Tier 1 (Outstanding) for TMT, Labour & Employment, Private Equity, Regulatory and Tax

**FT Innovative Lawyers Asia Pacific 2019 Awards:** NDA ranked 2nd in the Most Innovative Law Firm category (Asia-Pacific Headquartered)

**RSG-Financial Times:** India's Most Innovative Law Firm  
*2019, 2017, 2016, 2015, 2014*

## Research Papers

**Privacy & Data: India's Turn to Bat on the World Stage**

May 31, 2020

**Introduction to Cross-Border Insolvency**

April 30, 2020

**Don't Mind: You've been Acquired!**

April 28, 2020

## Research Articles

**Chambers Global Practice Guide: Gaming Laws**

December 19, 2019

**The Tips and Traps to Avoid When Investing in India**

December 31, 2018

**Evolving HR Law: Giving GCs**

for Medical Research's (ICMR) Ethical Guidelines for Biomedical Research on Human Participants, 2006 had issued draft guidelines for 'compensation to participants for research related injuries' some years back but these guidelines were, eventually, not implemented. In the absence of clear guidelines, there is no uniformity in the amount of compensation and the sponsor companies follow different parameters in deciding such amounts payable. This has led to dissatisfaction on the part of the study subject or his/her relatives. At the same time, several Non-Governmental Organizations have raised concerns over the incidences of injury and death to the study subjects.

The Drugs Technical Advisory Board (DTAB), under the chairmanship of the Director General of Health Services (DGHS), who is the ex-officio chairman of the Board in a meeting held recently, concluded that guidelines need to be issued in connection with the compensation to the study subjects. Consequently, DTAB has directed DCGI to issue guidelines on providing proper compensation to the victims of the trials. The proposed guidelines are expected to include various norms and conditions as well as specific procedures to decide on the amount of compensation that will be payable. The proposed guidelines would apply to all clinical research, irrespective of who has sponsored them.

Additionally, the DTAB has also decided that the independent ethics committee (IEC) involved in clinical trials will have to be registered with the drugs authority mandatorily. The DCGI is expected to issue guidelines in this regard as well. It may be recalled that, a couple of years ago, the DCGI had made it mandatory for all clinical trials being conducted in India to be registered with the Clinical Trials Registry.

Normally, institutions that are involved in the conduct of clinical trials are required to have the IEC in place. The IEC has been conferred with certain powers under law to monitor clinical trials. However, there have been instances recently when the authorities have received several complaints against such IECs raising concerns in respect of the independent nature of the IECs and the manner in which they grant approvals for the trials. Mandatory registration of the IEC is likely to bring about transparency in the conduct of clinical trials and help in increasing the confidence of the public at large.

**- Khushboo Baxi, Dr. Milind Antani & Gowree Gokhale**

#### DISCLAIMER

The contents of this hotline should not be construed as legal opinion. View detailed disclaimer.

This Hotline provides general information existing This is not a Spam mail. You have received this at the time of preparation. The Hotline is intended mail because you have either requested for it or as a news update and Nishith Desai Associates someone must have suggested your name. Since neither assumes nor accepts any responsibility for India has no anti-spamming law, we refer to the any loss arising to any person acting or refraining US directive, which states that a mail cannot be from acting as a result of any material contained in considered Spam if it contains the sender's contact this Hotline. It is recommended that professional information, which this mail does. In case this mail advice be taken based on the specific facts and doesn't concern you, please unsubscribe from circumstances. This Hotline does not substitute mailing list. the need to refer to the original pronouncements.

#### Sleepless Nights?

June 01, 2017

#### Audio

##### **Seminar: Possible Last Window for the Start-Up Community's Say on Proposed Privacy Law**

February 19, 2020

##### **Webinar: India Budget 2020: Implications for the International Community**

February 05, 2020

##### **Webinar: A New Dawn for Privacy in India: the Personal Data Protection Bill, 2019**

December 17, 2019

#### NDA Connect

Connect with us at events, conferences and seminars.

#### NDA Hotline

[Click here to view Hotline archives.](#)

#### Video

##### **NDA cCep - Client Continuing Education Program**

##### **Big Deal: Experts discuss how Facebook-Jio deal could impact FDI inflows into India (May 01, 2020)**

**CNBC TV18 Startup Street**